PGDIS position statement on the transfer of mosaic embryos 2021. Article

Leigh, D, Cram, DS, Rechitsky, S et al. (2022). PGDIS position statement on the transfer of mosaic embryos 2021. . 45(1), 19-25. 10.1016/j.rbmo.2022.03.013

cited authors

  • Leigh, D; Cram, DS; Rechitsky, S; Handyside, A; Wells, D; Munne, S; Kahraman, S; Grifo, J; Katz-Jaffe, M; Rubio, C; Viotti, M; Forman, E; Xu, K; Gordon, T; Madjunkova, S; Qiao, J; Chen, Z-J; Harton, G; Gianaroli, L; Simon, C; Scott, R; Simpson, JL; Kuliev, A

fiu authors


  • Chromosome testing strategies, such as preimplantation genetic testing for aneuploidy (PGT-A), improve initial IVF outcomes by avoiding unwitting transfer of aneuploid embryos in morphology-based selection practices. Newer technologies have revealed that some embryos may appear to have intermediate whole chromosome (or parts of a chromosome termed segmental) copy number results suggesting trophectoderm mosaicism. An embryo with a trophectoderm mosaic-range result may be the only option for transfer for some patients. Recent data suggest that such mosaic embryos can be transferred without added risk of abnormal birth outcomes but may be associated with increased implantation failure and miscarriage rates, with higher values of mosaicism appearing to be less favourable for producing good outcomes. In this Position Statement, we provide guidance to laboratories, clinics, clinicians and counsellors to assist in discussions on the utility and transfer of mosaic embryos.

publication date

  • July 1, 2022


  • Aneuploidy
  • Blastocyst
  • Embryo Transfer
  • Female
  • Genetic Testing
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Mosaicism
  • Pregnancy
  • Preimplantation Diagnosis

Digital Object Identifier (DOI)


  • Print-Electronic

start page

  • 19

end page

  • 25


  • 45


  • 1